Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro.
about
XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cellApoptosis inducing effects of Kuding tea polyphenols in human buccal squamous cell carcinoma cell line BcaCD885.Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses.X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma.Targeting endogenous inhibitors of apoptosis for treatment of cancer, stroke and multiple sclerosis.Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.Inhibitor of apoptosis proteins: new therapeutic targets in hematological cancer?Apoptosis-based therapies and drug targets.A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma.Antisense oligonucleotides in the treatment of bladder cancer.Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function.Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain.Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progressionInhibitor of apoptosis proteins as targets for anticancer therapy.X-linked inhibitor of apoptosis protein as a therapeutic target.X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer modelPrognostic significance of XIAP and NF-κB expression in esophageal carcinoma with postoperative radiotherapyEmerging apoptosis agonists for bladder cancer.Small-molecule pan-IAP antagonists: a patent review.Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets.ApoCanD: Database of human apoptotic proteins in the context of cancer.Immunohistochemical detection of XIAP in melanoma.Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder.Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer.Molecular targeting of Bcl-2 overcomes prostate cancer cell adaptation to XIAP gene downregulation.Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis.Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.Chemosensitization effects of XIAP downregulation in K562 leukemia cells.Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics.Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP).Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice.Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder.
P2860
Q30354484-81018CE9-B9FB-4F61-BC68-5F6AA8EB38A6Q34091735-31BAC044-6D5D-4556-AEC3-06D1FC5F4B10Q34557323-8AC6223A-DD1A-4A12-B386-43E37B6AC162Q35078238-C8CF18F3-9B98-4DCA-AD04-0D5BEC7F57FEQ35782897-21C82CB4-C61D-4CFC-B37C-D44A162A639AQ35847722-07BD93BD-7A63-42C1-A9C8-77B7E370F385Q35905166-7700F80D-51D0-4B06-A8D7-9614BC858B2DQ36017772-A21D952B-7D9C-4265-95B0-00558AECDE8DQ36040441-940E3E0A-06FE-45BE-816E-ECA0BC9E0A44Q36040819-13E4BCEF-C968-4299-8B76-A86B8FC58FC6Q36274969-8500358C-E2B5-409D-916E-59E23F5C630FQ36334885-2037F6E4-DB23-44D7-896D-A6F2BD246C23Q36491838-038149CE-77F7-451F-9E2D-CF555070FBEAQ36615251-3B23FF35-C8A4-4D30-B33B-F15DC1786802Q36950485-A4DF9439-DF3D-4ED2-8984-191E465A3267Q37008849-65D078DC-538D-4AB4-829E-6BDE8ACEEB70Q37260295-F8148B28-CE23-453C-A0BE-515DDC542EC3Q37284619-48586125-14BF-40E4-A2B6-96AD4AE5FDD1Q37601481-554519F8-DE7A-4524-89BD-5E71929C4F9DQ37680967-664E51BB-7FC9-4FC3-8744-7259C1F52E03Q37875078-2C1652D4-2694-4DC2-A3ED-B11B3B89FCE1Q38333966-28C80710-F1D7-4ABB-904D-DCFE7EEF584CQ38427860-7232507C-6929-4119-800C-CDBC9F932749Q38992743-2DF0D555-97DC-4D43-AACA-77BC79729008Q39437240-0D9E3D72-E56D-4C50-BCCB-43D2C8BE5447Q39982891-8EDF28EB-8070-4A60-9183-A3B22B8BFAEFQ40011719-82C9B250-394C-4C4C-9E67-90A3C93A06E0Q40163044-E05F04AD-C0F2-4A9F-A993-27F2E70561B0Q40298175-77B926B7-F7AA-4017-9BCA-6772EBABEAB3Q40463082-05C5AAD1-40D9-492F-9516-E0D4FF60082EQ40513940-C05DB40E-EF27-4381-AB4D-4F7639220D6CQ40576657-419B34B6-FA65-4F7D-B8A8-51370E531D12Q40612863-958403F1-65BB-46B3-B957-053F7636D76AQ45862336-22C9A5A0-49A1-478E-BB5A-A90D423A2F2EQ49246529-D1DF4E8D-9635-4707-BF13-3281BFC1029BQ54588466-3A34A118-AFCF-4E77-84FC-E04274FF1EB2
P2860
Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Role of XIAP in the malignant ...... tidrug-resistant TCC in vitro.
@en
Role of XIAP in the malignant phenotype of transitional cell cancer
@nl
type
label
Role of XIAP in the malignant ...... tidrug-resistant TCC in vitro.
@en
Role of XIAP in the malignant phenotype of transitional cell cancer
@nl
prefLabel
Role of XIAP in the malignant ...... tidrug-resistant TCC in vitro.
@en
Role of XIAP in the malignant phenotype of transitional cell cancer
@nl
P2093
P356
P1476
Role of XIAP in the malignant ...... tidrug-resistant TCC in vitro.
@en
P2093
Kota Takahashi
Noboru Hara
Takashi Kasahara
Vladimir Bilim
Yoshihiko Tomita
P356
10.1002/IJC.10776
P577
2003-01-01T00:00:00Z